Global Gene Synthesis Market is projected to register a substantial CAGR of 22.9% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
Global Gene Synthesis Market, By Component ( Synthesizer, Consumables, and Software & Services), Gene Type (Standard Gene, Express Gene, Complex Gene, and Others), Gene Synthesis Type (Gene Library Synthesis, and Custom Gene Synthesis), Application (Synthetic Biology, Genetic Engineering, Vaccine Design, Therapeutic Antibodies, and Others), Method (Solid Phase Synthesis, CHIP Based DNA Synthesis, and PCR Based Enzyme Synthesis), End User (Academic & Research Institutes, Diagnostic Laboratories, Biotech & Pharmaceutical Companies, and Others), Distribution Channel (Direct Tender, Online Distribution, and Third Party Distribution), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Switzerland, Netherlands, Belgium, Ireland, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Australia, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt, and Rest of Middle East and Africa) Industry Trends & Forecast to 2029.
Some of the major factors contributing to the growth of the global gene synthesis market are:
- Increased prevalence of chronic infectious diseases
- Expansion of synthetic biology
- Rising interest in gene synthesis in the field of molecular biology
- Rising adoption of gene therapy
Market Players:
Some of the key market players in the Global gene synthesis market are listed below:
- Twist Bioscience
- Thermo Fisher Scientific Inc.
- GenScript
- Merck KGaA
- Integrated DNA Technologies, Inc.
- Bio Basic Inc.
- trenzyme GmbH
- Others
TABLE OF CONTENTS
1 INTRODUCTION 40
- 1.1 OBJECTIVES OF THE STUDY 40
- 1.2 MARKET DEFINITION 40
- 1.3 OVERVIEW OF GLOBAL GENE SYNTHESIS MARKET 40
- 1.4 CURRENCY AND PRICING 42
- 1.5 LIMITATION 42
- 1.6 MARKETS COVERED 43
2 MARKET SEGMENTATION 45
- 2.1 MARKETS COVERED 45
- 2.2 GEOGRAPHIC SCOPE 46
- 2.3 YEARS CONSIDERED FOR THE STUDY 47
- 2.4 CURRENCY AND PRICING 47
- 2.5 RESEARCH METHODOLOGY 48
- 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
- 2.7 MULTIVARIATE MODELLING 52
- 2.8 COMPONENT SEGMENT LIFELINE CURVE 52
- 2.9 DBMR MARKET POSITION GRID 53
- 2.10 VENDOR SHARE ANALYSIS 55
- 2.11 MARKET APPLICATION COVERAGE GRID 56
- 2.12 THE CATEGORY VS TIME GRID 57
- 2.13 SECONDARY SOURCES 58
- 2.14 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 62
- 4.1 PESTEL 65
- 4.2 PORTER'S FIVE FORCES MODEL 66
5 GLOBAL GENE SYNTHESIS MARKET: REGULATIONS 67
6 MARKET OVERVIEW 71
- 6.1 DRIVERS 73
- 6.1.1 INCREASED PREVALENCE OF CHRONIC INFECTIOUS DISEASES 73
- 6.1.2 RISING ADOPTION OF GENE THERAPY 73
- 6.1.3 EXPANSION OF SYNTHETIC BIOLOGY 74
- 6.1.4 RISING INTEREST OF GENE SYNTHESIS IN THE FIELD OF MOLECULAR BIOLOGY 74
- 6.2 RESTRAINTS 75
- 6.2.1 LACK OF TRAINED PROFESSIONALS 75
- 6.2.2 ETHICAL ISSUES 75
- 6.2.3 LONG APPROVAL PROCESS 75
- 6.3 OPPORTUNITIES 76
- 6.3.1 RISE IN HEALTHCARE EXPENDITURE 76
- 6.3.2 STRATEGIC INITIATIVES BY KEY PLAYERS 76
- 6.3.3 RISING DEMAND FOR CUSTOMIZED MEDICATIONS 77
- 6.4 CHALLENGES 77
- 6.4.1 TECHNICAL LIMITATIONS ACROSS PRODUCTION PROCESS 77
- 6.4.2 LACK OF WELL DEFINED PATENT SYSTEM 78
7 GLOBAL GENE SYNTHESIS MARKET, BY COMPONENT 79
- 7.1 OVERVIEW 80
- 7.2 SOFTWARE & SERVICES 83
- 7.3 CONSUMABLES 83
- 7.3.1 REAGENTS 84
- 7.3.2 ASSAYS 84
- 7.3.3 PROBES & DYES 84
- 7.3.4 OTHERS 84
- 7.4 SYNTHESIZER 84
- 7.4.1 COLUMN-BASED SYNTHESIZERS 85
- 7.4.2 MICROARRAY-BASED SYNTHESIZERS 85
8 GLOBAL GENE SYNTHESIS MARKET, BY GENE TYPE 86
- 8.1 OVERVIEW 87
- 8.2 STANDARD GENE 90
- 8.3 COMPLEX GENE 90
- 8.4 EXPRESS GENE 91
- 8.5 OTHERS 91
9 GLOBAL GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE 92
- 9.1 OVERVIEW 93
- 9.2 CUSTOM GENE SYNTHESIS 96
- 9.2.1 STANDARD GENE 96
- 9.2.2 COMPLEX GENE 96
- 9.2.3 EXPRESS GENE 96
- 9.2.4 OTHERS 97
- 9.3 GENE LIBRARY SYNTHESIS 97
- 9.3.1 STANDARD GENE 97
- 9.3.2 COMPLEX GENE 97
- 9.3.3 EXPRESS GENE 98
- 9.3.4 OTHERS 98
10 GLOBAL GENE SYNTHESIS MARKET, BY APPLICATION 99
- 10.1 OVERVIEW 100
- 10.2 SYNTHETIC BIOLOGY 103
- 10.2.1 CUSTOM GENE SYNTHESIS 103
- 10.2.2 GENE LIBRARY SYNTHESIS 103
- 10.3 GENETIC ENGINEERING 104
- 10.3.1 CUSTOM GENE SYNTHESIS 104
- 10.3.2 GENE LIBRARY SYNTHESIS 104
- 10.4 THERAPEUTIC ANTIBODIES 104
- 10.4.1 CUSTOM GENE SYNTHESIS 105
- 10.4.2 GENE LIBRARY SYNTHESIS 105
- 10.5 VACCINE DESIGN 105
- 10.5.1 CUSTOM GENE SYNTHESIS 106
- 10.5.2 GENE LIBRARY SYNTHESIS 106
- 10.6 OTHERS 107
11 GLOBAL GENE SYNTHESIS MARKET, BY METHOD 108
- 11.1 OVERVIEW 109
- 11.2 PCR-BASED ENZYME SYNTHESIS 112
- 11.3 CHIP-BASED DNA SYNTHESIS 112
- 11.4 SOLID BASED SYNTHESIS 112
12 GLOBAL GENE SYNTHESIS MARKET, BY END USER 114
- 12.1 OVERVIEW 115
- 12.2 ACADEMIC & RESEARCH INSTITUTE 118
- 12.3 BIOTECH & PHARMACEUTICAL COMPANIES 118
- 12.4 DIAGNOSTIC LABORATORIES 118
- 12.5 OTHERS 119
13 GLOBAL GENE SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL 120
- 13.1 OVERVIEW 121
- 13.2 DIRECT TENDER 124
- 13.3 ONLINE DISTRIBUTION 124
- 13.4 THIRD PARTY DISTRIBUTORS 124
14 GLOBAL GENE SYNTHESIS MARKET, BY REGION 126
- 14.1 OVERVIEW 127
- 14.2 NORTH AMERICA 133
- 14.2.1 U.S. 143
- 14.2.2 CANADA 147
- 14.2.3 MEXICO 151
- 14.3 EUROPE 155
- 14.3.1 GERMANY 165
- 14.3.2 U.K. 169
- 14.3.3 ITALY 173
- 14.3.4 SPAIN 177
- 14.3.5 FRANCE 181
- 14.3.6 NETHERLANDS 185
- 14.3.7 RUSSIA 189
- 14.3.8 SWITZERLAND 193
- 14.3.9 TURKEY 197
- 14.3.10 BELGIUM 201
- 14.3.11 REST OF EUROPE 205
- 14.4 ASIA-PACIFIC 206
- 14.4.1 CHINA 217
- 14.4.2 JAPAN 221
- 14.4.3 INDIA 225
- 14.4.4 SOUTH KOREA 229
- 14.4.5 AUSTRALIA 233
- 14.4.6 SINGAPORE 237
- 14.4.7 MALAYSIA 241
- 14.4.8 THAILAND 245
- 14.4.9 INDONESIA 249
- 14.4.10 PHILIPPINES 253
- 14.4.11 REST OF ASIA-PACIFIC 257
- 14.5 SOUTH AMERICA 258
- 14.5.1 BRAZIL 268
- 14.5.2 ARGENTINA 272
- 14.5.3 REST OF SOUTH AMERICA 276
- 14.6 MIDDLE EAST &AFRICA 277
- 14.6.1 SAUDI ARABIA 287
- 14.6.2 SOUTH AFRICA 291
- 14.6.3 U.A.E. 295
- 14.6.4 ISRAEL 299
- 14.6.5 EGYPT 303
- 14.6.6 REST OF MIDDLE EAST & AFRICA 307
15 GLOBAL GENE SYNTHESIS MARKET: COMPANY LANDSCAPE 308
- 15.1 COMPANY SHARE ANALYSIS: GLOBAL 308
- 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 309
- 15.3 COMPANY SHARE ANALYSIS: EUROPE 310
- 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 311
16 SWOT ANALYSIS 312
17 COMPANY PROFILE 313
- 17.1 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER) 313
- 17.1.1 COMPANY SNAPSHOT 313
- 17.1.2 COMPANY SHARE ANALYSIS 313
- 17.1.3 PRODUCT PORTFOLIO 314
- 17.1.4 RECENT DEVELOPMENTS 314
- 17.2 THERMO FISHER SCIENTIFIC INC. 315
- 17.2.1 COMPANY SNAPSHOT 315
- 17.2.2 REVENUE ANALYSIS 315
- 17.2.3 COMPANY SHARE ANALYSIS 316
- 17.2.4 PRODUCT PORTFOLIO 316
- 17.2.5 RECENT DEVELOPMENT 317
- 17.3 EUROFINS SCIENTIFIC 318
- 17.3.1 COMPANY SNAPSHOT 318
- 17.3.2 REVENUE ANALYSIS 318
- 17.3.3 COMPANY SHARE ANALYSIS 319
- 17.3.4 SERVICE PORTFOLIO 319
- 17.3.5 RECENT DEVELOPMENT 320
- 17.4 MERCK KGAA 321
- 17.4.1 COMPANY SNAPSHOT 321
- 17.4.2 REVENUE ANALYSIS 321
- 17.4.3 COMPANY SHARE ANALYSIS 322
- 17.4.4 PRODUCT PORTFOLIO 322
- 17.4.5 RECENT DEVELOPMENT 323
- 17.5 KANEKA EUROGENTEC S.A. 324
- 17.5.1 COMPANY SNAPSHOT 324
- 17.5.2 REVENUE ANALYSIS 324
- 17.5.3 COMPANY SHARE ANALYSIS 325
- 17.5.4 PRODUCT PORTFOLIO 325
- 17.5.5 RECENT DEVELOPMENTS 326
- 17.6 ANSA BIOTECHNOLOGIES, INC 327
- 17.6.1 COMPANY SNAPSHOT 327
- 17.6.2 PRODUCT PORTFOLIO 327
- 17.6.3 RECENT DEVELOPMENTS 327
- 17.7 ATD BIO LTD 328
- 17.7.1 COMPANY SNAPSHOT 328
- 17.7.2 REVENUE ANALYSIS 328
- 17.7.3 PRODUCT PORTFOLIO 329
- 17.7.4 RECENT DEVELOPMENTS 329
- 17.8 ATG:BIOSYNTHETICS GMBH 330
- 17.8.1 COMPANY SNAPSHOT 330
- 17.8.2 PRODUCT PORTFOLIO 330
- 17.8.3 RECENT DEVELOPMENTS 330
- 17.9 AZENTUS US, INC (2021) 331
- 17.9.1 COMPANY SNAPSHOT 331
- 17.9.2 REVENUE ANALYSIS 331
- 17.9.3 PRODUCT PORTFOLIO 332
- 17.9.4 RECENT DEVELOPMENT 332
- 17.10 BBI LIFESCIENCES CORPORATION 333
- 17.10.1 COMPANY SNAPSHOT 333
- 17.10.2 PRODUCT PORTFOLIO 333
- 17.10.3 RECENT DEVELOPMENTS 333
- 17.11 BIO BASIC INC. 334
- 17.11.1 COMPANY SNAPSHOT 334
- 17.11.2 PRODUCT PORTFOLIO 334
- 17.11.3 RECENT DEVELOPMENTS 334
- 17.12 BIOCAT GMBH 335
- 17.12.1 COMPANY SNAPSHOT 335
- 17.12.2 PRODUCT PORTFOLIO 335
- 17.12.3 RECENT DEVELOPMENTS 335
- 17.13 BIONEER PACIFIC 336
- 17.13.1 COMPANY SNAPSHOT 336
- 17.13.2 PRODUCT PORTFOLIO 336
- 17.13.3 RECENT DEVELOPMENT 336
- 17.14 BOSTER BIOLOGICAL TECHNOLOGY 337
- 17.14.1 COMPANY SNAPSHOT 337
- 17.14.2 SERVICE PORTFOLIO 337
- 17.14.3 RECENT DEVELOPMENT 337
- 17.15 CSBIO 338
- 17.15.1 COMPANY SNAPSHOT 338
- 17.15.2 PRODUCT PORTFOLIO 338
- 17.15.3 RECENT DEVELOPMENTS 338
- 17.16 CREATIVE BIOGENE 339
- 17.16.1 COMPANY SNAPSHOT 339
- 17.16.2 RODUCTPORTFOLIO 339
- 17.16.3 RECENT DEVELOPMENT 339
- 17.17 EVONETIX 340
- 17.17.1 COMPANY SNAPSHOT 340
- 17.17.2 PRODUCT PORTFOLIO 340
- 17.17.3 RECENT DEVELOPMENTS 341
- 17.18 EXONBIO 342
- 17.18.1 COMPANY SNAPSHOT 342
- 17.18.2 PRODUCT PORTFOLIO 342
- 17.18.3 RECENT DEVELOPMENT 342
- 17.19 GCC BIOTECH (INDIA) PVT. LTD. 343
- 17.19.1 COMPANY SNAPSHOT 343
- 17.19.2 PRODUCT PORTFOLIO 343
- 17.19.3 RECENT DEVELOPMENT 343
- 17.20 GINKGO BIOWORKS (2021) 344
- 17.20.1 COMPANY SNAPSHOT 344
- 17.20.2 REVENUE ANALYSIS 344
- 17.20.3 PRODUCT PORTFOLIO 345
- 17.20.4 RECENT DEVELOPMENTS 345
- 17.21 GENERAL BIOSYSTEMS INC 346
- 17.21.1 COMPANY SNAPSHOT 346
- 17.21.2 PRODUCT PORTFOLIO 346
- 17.21.3 RECENT DEVELOPMENTS 346
- 17.22 GENSCRIPT 347
- 17.22.1 COMPANY SNAPSHOT 347
- 17.22.2 REVENUE ANALYSIS 347
- 17.22.3 PRODUCT PORTFOLIO 348
- 17.22.4 RECENT DEVELOPMENTS 348
- 17.23 MACROGEN CO., LTD. (A SUBSIDIARY OF MACROGEN, INC) 349
- 17.23.1 COMPANY SNAPSHOT 349
- 17.23.2 REVENUE ANALYSIS 349
- 17.23.3 PRODUCT PORTFOLIO 350
- 17.23.4 RECENT DEVELOPMENTS 350
- 17.24 NZYTECH, LDA. - GENES AND ENZYMES. 351
- 17.24.1 COMPANY SNAPSHOT 351
- 17.24.2 PRODUCT PORTFOLIO 351
- 17.24.3 RECENT DEVELOPMENT 351
- 17.25 ORIGENE TECHNOLOGIES, INC 352
- 17.25.1 COMPANY SNAPSHOT 352
- 17.25.2 PRODUCT PORTFOLIO 352
- 17.25.3 RECENT DEVELOPMENTS 352
- 17.26 PROMAB BIOTECHNOLOGIES 353
- 17.26.1 COMPANY SNAPSHOT 353
- 17.26.2 PRODUCT PORTFOLIO 353
- 17.26.3 RECENT DEVELOPMENTS 353
- 17.27 PROTEOGENIX 354
- 17.27.1 COMPANY SNAPSHOT 354
- 17.27.2 PRODUCT PORTFOLIO 354
- 17.27.3 RECENT DEVELOPMENTS 354
- 17.28 SYNBIO TECHNOLOGIES 355
- 17.28.1 COMPANY SNAPSHOT 355
- 17.28.2 PRODUCT PORTFOLIO 355
- 17.28.3 RECENT DEVELOPMENTS 356
- 17.29 TRENZYME GMBH 357
- 17.29.1 COMPANY SNAPSHOT 357
- 17.29.2 PRODUCT PORTFOLIO 357
- 17.29.3 RECENT DEVELOPMENTS 357
- 17.30 TWIST BIOSCIENCE 358
- 17.30.1 COMPANY SNAPSHOT 358
- 17.30.2 REVENUE ANALYSIS 358
- 17.30.3 PRODUCT PORTFOLIO 359
- 17.30.4 RECENT DEVELOPMENTS 359
18 QUESTIONNAIRE 360
19 RELATED REPORTS 363